In a cohort of 126 patients with NSCLC, a prediction formula incorporating CD62Llo CD4+ T cells and CD25+ Foxp3+ Tregs at baseline could discriminate between patients with a BOR of CR, PR, or SD and those with PD at 9 weeks after start of αPD‐1 therapy.63 The gene discussed is IL2RA; the disease is non-small cell lung carcinoma.